TAIMEI TECH
Listing Date | 2024/10/08 |
Listing Price | 13.000 |
- Subscription Rate156.33x
- Guarantee One Lot Size40 lot
- One Lot Success Rate2.69%
Listing Date | 2024/10/08 |
Listing Price | 13.000 |
Zhejiang Taimei Medical Technology Co is a digital solution provider focused on the pharmaceutical and medical device industry in China. It designs and delivers industry-specific software and digital services that facilitates the research and development as well as commercialization of pharmaceuticals and medical devices.
--
The Group’s solutions for the pharmaceutical and medical device industry consist of cloud-based software, including SaaS products and customized products, and digital services. Its SaaS products and digital services are primarily offered through digital collaboration platforms, including TrialOS and PharmaOS.
--
The Group is the largest digital solution provider for pharmaceutical and medical device R&D and commercialization in China in terms of revenue in 2023, taking up a market share of 5.9%, according to CIC. As of March 31, 2024, it had served over 1,400 pharmaceutical companies and contract research organizations, including 21 out of the top 25 global pharmaceutical companies and 90 of the top 100 Chinese pharmaceutical innovators.
--
The Group’s customers mainly included pharmaceutical and medical device companies, third-party service providers (e.g. CROs), clinical research institutions and others.
Market | Hong Kong (Main Board) |
Business Nature | Health Care |
Major Business Area | China |
Board Lot | 200 |
No. of Offer Shares | 25.78M H shares |
No. of International Offer Shares | 12.89M H shares |
No. of HK Offer Shares | 12.89M H shares |
Offer Price | $10.00 - $13.00 |
Stock Code | 2576 |
Sponsor(s) | Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited |
Underwriter(s) | Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, Huatai Financial Holdings (Hong Kong) Limited, CMB International Capital Limited, CCB International Capital Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited, Valuable Capital Limited |
Application Period | Sep 27 (Fri) - noon, Oct 03 (Thu) |
Price Determination Date | Oct 04 (Fri) |
Result Announcement Date | On or before Oct 07 (Mon) |
Result Announcement Date | On or before Oct 07 (Mon) |
Result Announcement Date | On or before Oct 08 (Tue) |
Dealings in Shares commence on | Oct 08, 2024. (Tue) |
Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
% of total shares reallocated to HK Offer | 30% | 40% | 50% |
Offer Price | $10.00 - $13.00 |
Capitalization (H Shares) | 1.97B - 2.56B |
NAV / share ($) | $2.02 - $2.13 (Unaudited pro forma adj NAV / share) |
Assuming the offer price being at HKD 11.5, the net proceeds raised would be HKD 185.70M, of which |
35% : Improve and upgrade TrialOS Platform and PharmaOS Platform and their respective cloud-based software and digital services |
30% : Improve core technology and R&D capabilities |
10% : Strengthen sales and marketing capabilities |
15% : Pursue strategic investments and acquisitions to expand existing product and service offerings, expand customer base and enhance technology capabilities |
10% : Working capital |
08/10/2024 16:08 |
{New Stock}TAIMEI TECH(02576) ends down 29.23% at HK$9.2 |
08/10/2024 09:20 |
{New Stock}TAIMEI TECH(02576) opens down 13.54% at HK$11.24 |
07/10/2024 18:35 |
{New Stock}TAIMEI TECH ends down 13.23% on grey market |
07/10/2024 16:20 |
{New Stock}TAIMEI TECH down 10.77% at HK$11.6 on grey market |
Prospectus | Chinese Version | English Version |
Remark: | The above information is referenced from the prospectus. |
All data is calculated from the non- exercise rights(if applicable). |
Currency | : |
Listing Price | : |
Board Lot | : |
Admission Fee* |
: |
Subscribing Lot | : |
Subscribing Fee | : |
Subscribing Amount | : |